JPMorgan says this biotech stock can more than double following steep declines
JPMorgan initiated coverage of Neurogene with an overweight rating and a $60 price target, implying 132% upside. The bank's optimism is based on the company's gene therapy for Rett syndrome. Neurogene shares have fallen 32% over the past three months, partly due to broader biotech sector declines and softer Q2 results. The company plans to release new trial data in 2027, which JPMorgan sees as a potential catalyst.
How this was made
The 30-second read
Why it matters
JPMorgan's overweight rating and $60 target suggest a strong belief in the company's gene‑therapy pipeline, especially NGN‑401 for Rett syndrome.
Market read
Analyst coverage can trigger short‑term buying pressure, especially for a micro‑cap biotech with a large upside thesis.
What to watch
Pending trial data in 2027 and higher R&D costs could temper upside.
Background
Neurogene (NGNE) has fallen ~32% over three months amid a biotech pullback and softer Q2 results.
Ticker impact
JPMorgan initiated coverage on Neurogene with an overweight rating and a $60 price target, a first‑report analyst upgrade.
potential upward pressure as investors price in the 132% upside target
New coverage and a substantial price target are fresh catalysts that can attract fresh capital.
Market effects
May lift sentiment in the broader biotech sector as coverage expands.
Limited to U.S. biotech investors.
Low global impact beyond sector peers.
Counterpoint
The stock's recent 32% decline may reflect underlying risks not captured by the upgrade.
Key entities
- companyNeurogene
Biotech firm developing gene‑therapy NGN‑401 for Rett syndrome.
- analystJPMorgan
Investment bank that initiated coverage with an overweight rating.
